Neumora Therapeutics (NMRA) Leases (2022 - 2026)

Neumora Therapeutics' Leases history runs 5 years deep, the most recent figure standing at $358000.0 for Q1 2026.

• In Q1 2026, Leases fell 60.22% year-over-year to $358000.0; the TTM figure through Mar 2026 stood at $358000.0 (down 60.22% YoY), while the FY2025 annual figure was $417000.0, down 76.53% from the prior year.
• Leases was $358000.0 for Q1 2026 at Neumora Therapeutics, down from $417000.0 in the prior quarter.
• In the past five years, Leases ranged from a high of $8.2 million in Q4 2022 to a low of $358000.0 in Q1 2026.
• Historically, Leases has averaged $2.8 million across 5 years, with a median of $2.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Leases slumped 38.43% in 2023, then slumped 84.68% in 2025.
• A 5-year view of Leases shows it stood at $8.2 million in 2022, then plunged by 38.43% to $5.1 million in 2023, then plunged by 64.94% to $1.8 million in 2024, then sank by 76.53% to $417000.0 in 2025, then retreated by 14.15% to $358000.0 in 2026.
• The last three Leases figures came in at $358000.0 (Q1 2026), $417000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.